Will this trial change my practice? ABSORB II trial (a bioresorbable vascular scaffold versus drug-eluting stent in coronary disease).
نویسندگان
چکیده
1.The Heart Hospital, University College London Hospitals UCLH, London, United Kingdom; 2. Deutsches Herzzentrum München, Technische Universität München and DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany; 3. Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands; 4. Department of Cardiology, Bern University Hospital, Bern, Switzerland; 5. Institute of Primary Health Care, University of Bern, Bern, Switzerland; 6. Department of Medicine, Faculty of Medicine, University of Kuwait and Chest Disease Hospital, University of Kuwait, Kuwait City, Kuwait
منابع مشابه
Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
OBJECTIVES The purpose of this study was to evaluate the economic impact of the Absorb bioresorbable vascular scaffold compared with the Xience everolimus-eluting stent in patients undergoing percutaneous coronary intervention. BACKGROUND The ABSORB III trial (Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease) demonstrated that the Absorb scaffold was noninferior to the X...
متن کاملThe first generation ABSORB BVS scaffold; to be or not to be?
In the routine treatment of coronary artery disease, balloon angioplasty has been replaced by stents. The use of bare-metal stents resulted in lower rates of restenosis and repeat revascularisations. Drug-eluting stents (DES), designed with thinner struts and anti-proliferative drugs, have further enhanced the efficacy and safety of percutaneous coronary intervention. Nevertheless, the new gene...
متن کاملBioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.
BACKGROUND The everolimus-eluting bioresorbable vascular scaffold (BVS) is designed to achieve results comparable to metallic drug-eluting stents at 1 year, with improved long-term outcomes. Whether the 1-year clinical and angiographic results of BVS are noninferior to current-generation drug-eluting stents has not been established. OBJECTIVES This study sought to evaluate the angiographic ef...
متن کاملBioresorbable vascular scaffold versus metallic stent in percutaneous coronary intervention: results of the AIDA trial
Drug-eluting stents have significantly improved the long-term outcomes of percutaneous coronary intervention (PCI) by decreasing the excessive growth of neointima. However, conventional stents have some limitations. PCI with a bioresorbable vascular scaffold (BVS) has emerged as an alternative since the presence of the prosthesis in the coronary artery is transient. A US Food and Drug Administr...
متن کاملComparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial
BACKGROUND Second-generation everolimus-eluting stents (EES) and third generation biolimus-eluting stents (BES) have been shown to be superior to first-generation paclitaxel-eluting stents (PES) and second-generation sirolimus-eluting stents (SES). However, neointimal proliferation and very late stent thrombosis is still an unresolved issue of drug-eluting stent (DES) implantation overall. The ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
دوره 11 3 شماره
صفحات -
تاریخ انتشار 2015